Description
Phosphorylated Tau217 (p-Tau217) has emerged as the most specific and early-appearing biomarker for Alzheimer’s Disease, often detectable 10–20 years before the onset of clinical symptoms. Our p-Tau217 Detection Kit (Digital Immunochip Method) provides a revolutionary solution for high-precision AD diagnosis using human plasma samples.
Key Features:
- Exceptional Diagnostic Accuracy: Research indicates that plasma p-Tau217 identifies AD-related pathology with high precision—comparable to invasive CSF biomarkers.
- Cutting-Edge Digital Immunochip Method: Utilizes a double-antibody sandwich assay and magnetic bead-based antigen-antibody complexes. Once loaded into microwells, individual signals are amplified and captured by high-resolution CCD detectors.
- Ultra-Sensitivity (Femtogram Level): When used with the Inspirer DX Analyzer, the system offers 1,000x greater sensitivity than traditional methods, enabling the detection of trace proteins at a limit of 2.5 fg/mL.
- Non-Invasive Convenience: Replaces painful spinal taps and expensive imaging with a simple blood-based test, making cognitive decline assessment more accessible and practical for elderly populations.
- Versatile Clinical & Research Utility: Essential for auxiliary AD diagnosis, differentiating non-AD dementia, monitoring disease progression, and evaluating therapeutic efficacy in drug R&D.
Technical Specifications:
- Product Name: Human phosphorylated Tau217 protein detection kit (digital immunochip method).
- Packing: 48 tests/box or 96 tests/box.
- Sample Type: Human Plasma.
- System Compatibility: Optimized for the Inspirer DX Analyzer.
